1Farrell G C. Non-alcoholic steatohepatitis: What is it, and why is it important in the Asia-pacific region? J Gastrenterol Hepatol, 2003,18: 124-138.
2Wanless IR, Lentz JS. Fatty liver hepatitis(steatohepatitis)and obese: an autopsy study with analysis of risk factors. Hepatology, 1990,12: 1106-1110.
3Silverman JF, O'Brien KF, Long S, et al. Liber pathology in morbidly obese patients with and without diabetes. Am J Gastroenterol, 1990,85: 1349-1355.
4Teli MR, James OFR, Burt JA, et al. The nature history of nonalcoholic fatty liver disease:a follow up study. Hepatology, 1995,22: 594-598.
5Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease, a spectrum of clinical and pathological severity. Gastrenterology, 1999,116: 1413-1419.
6Tominaga K, Kurata JH, Chen YK, et al. Prevalence of fatty liver in Japanese children and relationship to obesity. Dig Dis Sci, 1995,4: 2002-2009.
7Younossi ZM, Diehl AM, Ong JP, Nonalcoholic fatty disease: an agenda for clinical research. Hepatology, 2002,35: 746-752.
8Kruszzon D,Nainan QV,et al.The prevalence of hepatitis C virus infection in the United States,1988 through 1994[ J ].N Engl J med,1999,34(8):556-557
9Basaranoglu M,Acbay D,Sonsuz A.A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis[J].Hepatol,1999,31(2):384-385
10Harlander JC,Kwo PY,Cummings OW.Atorvastatin for the treatment of NASH[ J ].Gastroenterology,2001,120A:544,2767
